Addition Therapeutics closed a large financing to advance its PRINT (Precise RNA‑Mediated Insertion of Transgenes) platform, which uses RNA and retrotransposon biology delivered by lipid nanoparticles to insert payloads into a genomic safe site. The company announced fundraising totaling roughly $100–106.5 million and launched publicly with an all‑RNA, LNP‑based gene‑insertion strategy. Backers include philanthropic and institutional investors; Addition positions its approach as scalable, platform‑level gene therapy that avoids viral vectors. The financing will fund IND‑enabling studies and early clinical plans. Key technical and regulatory risks include insertional specificity, long‑term expression control, and demonstrating safety versus established AAV and integrating vector approaches.